Advertisement
Screener

BIO-RAD LABORATORIES, INC. (BIO) Overview

BIO-RAD LABORATORIES, INC. (BIO) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 13.85; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -19.55; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -12.70; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 11.67; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$229.62$257.83$289.51$325.08$365.01$409.862025-11-062026-11-06$205.73$271.20$357.51$471.29$621.27$818.992021-11-082026-11-06$158.36$222.50$312.62$439.23$617.12$867.062016-11-072026-11-06$50.45$89.10$157.37$277.94$490.91$867.062006-11-062026-11-06$0.83$3.32$13.35$53.67$215.72$867.061980-02-272026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$381.90
Previous close
$379.55
Change
$2.35
Change (%)
0.62%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

BIO
+25.37%
S&P 500
(m)

1 year

BIO
+40.63%
S&P 500
(m)

3 years

BIO
+5.97%
S&P 500
(m)

5 years

BIO
-49.30%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 13.85

-19.63-11.21-2.805.6114.0331 Mar 2025: estimate (m); actual 2.2931 Mar 2025(m)30 Jun 2025: estimate (m); actual 11.6730 Jun 2025(m)30 Sept 2025: estimate (m); actual -12.7030 Sept 2025(m)31 Mar 2026: estimate (m); actual -19.5531 Mar 2026(m)30 Jun 2026: estimate (m); actual 13.8530 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)13.85(m)(m)
1 Jan 202631 Mar 2026(m)-19.55(m)(m)
1 Jul 202530 Sept 2025(m)-12.70(m)(m)
1 Apr 202530 Jun 2025(m)11.67(m)(m)
1 Jan 202531 Mar 2025(m)2.29(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 27.85

-121.87-56.159.5775.29141.0131 Dec 2021: estimate (m); actual 140.8331 Dec 2021(m)31 Dec 2022: estimate (m); actual -121.7931 Dec 2022(m)31 Dec 2023: estimate (m); actual -21.8231 Dec 2023(m)31 Dec 2024: estimate (m); actual -65.3631 Dec 2024(m)31 Dec 2025: estimate (m); actual 27.8531 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)27.85(m)(m)
1 Jan 202431 Dec 2024(m)-65.36(m)(m)
1 Jan 202331 Dec 2023(m)-21.82(m)(m)
1 Jan 202231 Dec 2022(m)-121.79(m)(m)
1 Jan 202131 Dec 2021(m)140.83(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 651.00M ■ Earnings 371.40M — Profit margin 57.05%

-676.75M-90.0%-161.28M-25.1%354.18M39.9%869.65M104.9%30 Sept 2025: revenue 653.00M; earnings -341.90M; profit margin -52.36%30 Sept 202531 Dec 2025: revenue 693.20M*; earnings 720.00M*; profit margin 103.87%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 592.10M; earnings -527.10M; profit margin -89.02%31 Mar 202630 Jun 2026: revenue 651.00M; earnings 371.40M; profit margin 57.05%30 Jun 2026

31 Dec 2025 ■ Revenue 2.58B ■ Earnings 0.76B — Profit margin 29.42%

-4.40B-130.5%-1.74B-76.8%0.92B-23.2%3.57B30.4%31 Dec 2022: revenue 2.80B; earnings -3.63B; profit margin -129.45%31 Dec 202231 Dec 2023: revenue 2.67B; earnings -0.64B; profit margin -23.86%31 Dec 202331 Dec 2024: revenue 2.57B; earnings -1.84B; profit margin -71.86%31 Dec 202431 Dec 2025: revenue 2.58B; earnings 0.76B; profit margin 29.42%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$381.90(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$381.90High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning BIO

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Index membership
(m)
Employees
790.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
271.33K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-0.02%*
Total return · month
-2.12%*
Total return · quarter
28.64%*
Total return · half year
43.13%*
Total return · year to date
25.37%*
Total return · 1 year
40.63%*
Total return · 3 years
5.97%*
Total return · 5 years
-49.30%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

BIO-RAD LABORATORIES, INC. Overview

View more →

(m)

(m)

SEC CIK
12208
Industry (SIC)
3826 Laboratory Analytical Instruments
Country of operation
United States
Business address
1000 ALFRED NOBEL DRIVE, HERCULES, California, 94547, United States
Fiscal year end
1231
Phone
5107247000